ArticleCancer pathogenesis and therapy2026
Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD).
Article in Cancer pathogenesis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CYTOKINE SIGNALING REGULATES MULTIPLE STAGES OF GAMMA-HERPESVIRUS INFECTION IN MYELOID CELLS.bioRxiv : the preprint server for biology · 2026Article
- Superior outcomes with offspring B-leader-matched haploidentical versus older matched sibling donors in AL/MDS patients aged ≥40 years.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ruxolitinib (RUX) suppresses antiviral immunity in patients with hematologic diseases. For steroid-refractory acute graft-versus-host disease (aGVHD), studies have yielded conflicting results regarding whether RUX treatment increases the risk of Epstein-Barr virus (EBV) infection. However, in newly diagnosed aGVHD, the use of RUX raises concerns about the potential risk of EBV infection. This study aimed to evaluate the incidence of EBV reactivation and EBV-related posttransplant lymphoproliferative disease (EBV-PTLD) in patients receiving a regimen of 5 mg/day RUX combined with 1 mg·kg Method: In this retrospective cohort study, allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients were consecutively screened at the Chinese PLA General Hospital. Patients who developed grade II-IV aGVHD were retrospectively categorized on the basis of first-line treatment. The RUX plus steroid (RUX-steroid) group (5 mg/day RUX + 1 mg·kg Results: A total of 487 patients treated between January 2018 and December 2023 were included in this study, with a median follow-up of 26.6 months (range, 2.8-69.9). Among these patients, 105 received RUX (5 mg/day) plus methylprednisolone (1 mg·kg Conclusion: RUX was associated with an increased risk of EBV reactivation in patients after allo-HSCT but not with PTLD. Regular monitoring of the EBV viral load to enable timely intervention remains essential in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.